2018 Section 6 - Laryngology, Voice Disorders, and Bronchoesophalogy

Stachler et al

405. Blitzer A, Brin MF, Fahn S, et al. Localized injections of botu- linum toxin for the treatment of focal laryngeal dystonia (spas- tic dysphonia). Laryngoscope . 1988;98:193-197. 406. Troung DD, Rontal M, Rolnick M, et al. Double-blind con- trolled study of botulinum toxin in adductor spasmodic dys- phonia. Laryngoscope . 1991;101:630-634. 407. Cannito MP, Woodson GE, Murry T, et al. Perceptual analyses of spasmodic dysphonia before and after treatment. Arch Oto- laryngol Head Neck Surg . 2004;130:1393-1389. 408. Courey MS, Garrett CG, Billante CR, et al. Outcomes assess- ment following treatment of spasmodic dysphonia with botuli- num toxin. Ann Otol Rhinol Laryngol . 2000;109:819-822. 409. Watts C, Whurr R, Nye C. Botulinum toxin injections for the treatment of spasmodic dysphonia. Cochrane Database Syst Rev . 2004;(3):CD004327. 410. Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol . 2010;17:28-30. 411. Patel AB, Bansberg SF, Adler CH, et al. The Mayo Clinic Ari- zona spasmodic dysphonia experience: a demographic analysis of 718 patients. Ann Otol Rhinol Laryngol . 2015;124:859-863. 412. Namin AW, Christopher KM, Eisenbeis JF. Botulinum toxin dosing trends in spasmodic dysphonia over a 20-year period. J Voice . 2017;31:107-110. 413. Tang CG, Novakovic D, Mor N, et al. Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: a 15-year experience. Laryngoscope . 2016;126:678-681. 414. Patel NJ, Kerschner JE, Merati AL. The use of injectable col- lagen in the management of pediatric vocal unilateral fold paralysis. Int J Pediatr Otorhinolaryngol . 2003;67:1355-1360. 415. Chester MW, Stewart MG. Arytenoid adduction combined with medialization thyroplasty: an evidence-based review. Otolar- yngol Head Neck Surg . 2003;129:305-310. 416. Gardner GM, Altman JS, Balakrishnan G. Pediatric vocal fold medialization with silastic implant: intraoperative airway man- agement. Int J Pediatr Otorhinolaryngol . 2000;52:37-44. 417. Link DT, Rutter MJ, Liu JH, et al. Pediatric type I thyro- plasty: an evolving procedure. Ann Otol Rhinol Laryngol . 1999;108:1105-1110. 418. Orbelo DM, Duffy JR, Hughes Borst BJ, et al. Differences in botulinum toxin dosing between patients with adduc- tor spasmodic dysphonia and essential voice tremor. J Voice . 2014;28:123-127. 419. Payne S, Tisch S, Cole I, et al. The clinical spectrum of laryn- geal dystonia includes dystonic cough: observations of a large series. Mov Disord . 2014;29:729-735. 420. Ekbom DC, Garrett CG, Yung KC, et al. Botulinum toxin injec- tions for new onset bilateral vocal fold motion impairment in adults. Laryngoscope . 2010;120:758-763. 421. Ongkasuwan J, Courey M. The role of botulinum toxin in the management of airway compromise due to bilateral vocal fold paralysis. Curr Opin Otolaryngol Head Neck Surg . 2011;19:444-448. 422. Damrose EJ, Damrose JF. Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma. J Laryngol Otol . 2008;122:824-828. 423. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experi-

387. Ossoff RH, Koriwchak MJ, Netterville JL, et al. Difficulties in endoscopic removal of Teflon granulomas of the vocal fold. Ann Otol Rhinol Laryngol . 1993;102:405-412. 388. Daniero JJ, Garrett CG, Francis DO. Framework surgery for treatment of unilateral vocal fold paralysis. Curr Otorhinolar- yngol Rep . 2014;2:119-130. 389. Schneider B, Denk DM, Bigenzahn W. Functional results after external vocal fold medialization thyroplasty with the titanium vocal fold medialization implant. Laryngoscope . 2003;113:628-634. 390. Zeitels SM, Mauri M, Dailey SH. Medialization laryngoplasty with Gore-Tex for voice restoration secondary to glottal incom- petence: indications and observations. Ann Otol Rhinol Laryn- gol . 2003;112:180-184. 391. Cummings CW, Purcell LL, Flint PW. Hydroxylapatite laryn- geal implants for medialization: preliminary report. Ann Otol Rhinol Laryngol . 1993;102:843-851. 392. Paniello, RC, Edgar, JD, Kallogjeri, D, et al. Medialization versus reinnervation for unilateral vocal fold paralysis: a multicenter ran- domized clinical trial. Laryngoscope . 2011;121:2172-2179. 393. Zur KB, Carroll LM. Recurrent laryngeal nerve reinnerva- tion in children: acoustic and endoscopic characteristics pre- intervention and post-intervention. A comparison of treatment options. Laryngoscope . 2015;125:S1-S15. 394. Smith ME, Houtz DR. Outcomes of laryngeal reinnervation for unilateral vocal fold paralysis in children: associations with age and time since injury. Ann Otol Rhinol Laryngol . 2016;125:433-438. 395. Li M, Chen S, Wang W, et al. Effect of duration of denervation on outcomes of ansa-recurrent laryngeal nerve reinnervation. Laryngoscope . 2014;124:1900-1905. 396. Gray SD, Barkmeier J, Jones D, et al. Vocal evaluation of thyroplastic surgery in the treatment of unilateral vocal fold paralysis. Laryngoscope . 1992;102:415-421. 397. Kelchner LN, Stemple JC, Gerdeman E, et al. Etiology, patho- physiology, treatment choices, and voice results for unilateral adductor vocal fold paralysis: a 3-year retrospective. J Voice . 1999;13:592-601. 398. Rosen CA. Complications of phonosurgery: results of a national survey. Laryngoscope . 1998;108:1697-1703. 399. Truong DD, Bhidayasiri R. Botulinum toxin therapy of laryn- geal muscle hyperactivity syndromes: comparing different botulinum toxin preparations. Eur J Neurol . 2006;13:36-41. 400. Roy N. Differential diagnosis of muscle tension dysphonia and spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg . 2010;18:165-170. 401. Creighton FX, Hapner E, Klein A, et al. Diagnostic delays in spasmodic dysphonia: a call for clinician education. J Voice . 2015;29:592-594. 402. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope . 2001;111:218-226. 403. Sulica L. Contemporary management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg . 2004;12:543-548. 404. Stong BC, DelGaudio JM, Hapner ER, et al. Safety of simul- taneous bilateral botulinum toxin injections for abductor spasmodic dysphonia. Arch Otolaryngol Head Neck Surg . 2005;131:793-795.

72